Clinical Trial Update: Effect of Xolair on Airway Hyperresponsiveness [Phase 4]

View source ↗

Summary

Phase 4 study evaluating whether Xolair (omalizumab) improves airway hyperresponsiveness in allergic asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Creighton University | Conditions: Allergic Asthma | Phase 4 | Status: UNKNOWN